Pfizer Announces New Chief Internal Medicine Officer

New York, March 6, 2025 – Pfizer Inc. (NYSE: PFE) today announced that James List, M.D., Ph.D., has joined the company as Chief Internal Medicine Officer. In this role, Dr. List will oversee Pfizer’s Internal Medicine portfolio, from early discovery to late development, inclusive of Medical Affairs and Business Development strategies. He will be responsible for advancing Pfizer’s emerging pipeline of cardiovascular, metabolic, hematologic, and obesity medicines.

Dr. List is a world-class business and scientific leader with clinical experience in endocrinology as a faculty member at Harvard Medical School. Most recently, Dr. List served as Senior Vice President, Global Therapeutic Area Head for Cardiovascular & Metabolism at Janssen. In this role, he was accountable for drug discovery, clinical development, and external innovation in cardiovascular, metabolic, and retinal diseases across diverse modalities, including small molecules, peptides, biologics, RNA therapeutics, and AAV gene therapy. While at Janssen, Dr. List oversaw numerous cardiovascular and renal outcomes trials across therapeutic areas, which resulted in a multitude of regulatory approvals for new medicines and expanded indications.

Before joining Janssen, Dr. List was Vice President, Diabetes Development at Bristol-Myers Squibb, where he contributed to several key regulatory approvals.

Dr. List earned his M.D. and Ph.D. from the University of Minnesota and his undergraduate and Master’s degrees in Medical Microbiology and Philosophy of Science, respectively, at Stanford. His Ph.D. research focus was on viral pathogenesis, and his post-doctoral research at Massachusetts General Hospital (MGH) focused on GLP-1.  He completed his medical training at Brigham and Women’s Hospital, Boston Children’s Hospital and MGH. He is board certified in Internal Medicine, Pediatrics and Endocrinology, maintaining active medical licensure and certification in New Jersey and Massachusetts.

About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice
The information contained in this release is as of March 6, 2025. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed in any jurisdictions for any potential indication for Pfizer’s product candidates; whether and when any such applications that may be pending or filed for any of Pfizer’s product candidates may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy and, if approved, whether any such product candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pfizer’s product candidates; the impact of COVID-19 on our business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

Media Contact:

+1 (212) 733-1226
PfizerMediaRelations@Pfizer.com

Investor Contact:

+1 (212) 733-4848
IR@Pfizer.com